公开(公告)号：US10457707B2

公开(公告)日：2019-10-29

申请号：US16160724

申请日：2018-10-15

Applicant: St. Jude Children's Research Hospital

Inventor： Richard E. Lee ,  Ying Zhao ,  Liu Jiuyu

IPC: A61K38/00 ,  C07K9/00 ,  C07K11/02 ,  A61K38/12 ,  A61K31/407 ,  A61K38/14 ,  A61K45/06 ,  C07D498/14 ,  C07D498/22 ,  C07K7/06 ,  A61K9/00 ,  A61K47/02 ,  A61K9/20 ,  A61K38/15

Abstract: In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US10428305B2

公开(公告)日：2019-10-01

申请号：US15309362

申请日：2015-05-14

Applicant: National University of Singapore ,  St. Jude Children's Research Hospital, Inc.

Inventor： Dario Campana ,  David Shook ,  Masaru Imamura

IPC: C12N15/24 ,  C12N5/10 ,  C07K14/54 ,  C12N5/0783 ,  C12N15/62 ,  A61K35/17 ,  C12N5/00 ,  A61K38/20 ,  C07K14/705 ,  C07K19/00

Abstract: The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.

公开(公告)号：US20190127428A1

公开(公告)日：2019-05-02

申请号：US15794503

申请日：2017-10-26

Applicant: St. Jude Children's Research Hospital

Inventor： Joseph Paul Taylor ,  Peipei Zhang

IPC: C07K14/415 ,  C12N9/14 ,  C12N13/00

CPC classification number: C07K14/415 ,  C07K2319/00 ,  C12N9/14 ,  C12N13/00 ,  C12Y306/04012 ,  C12Y306/04013

Abstract: A nucleic acid molecule encoding a fusion protein composed of a plant cryptochrome at the amino terminus, and a GTPase-Activating Protein SH3 Domain-Binding Protein (G3BP) is provided for light-dependent, G3BP-mediated stress granule formation.

公开(公告)号：US10144770B2

公开(公告)日：2018-12-04

申请号：US14516880

申请日：2014-10-17

Applicant: National University of Singapore ,  St. Jude Children's Research Hospital ,  Unum Therapeutics Inc.

Inventor： Dario Campana ,  Ko Kudo ,  Charles Wilson ,  Kathleen McGinness

IPC: C07K14/735 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K14/705 ,  C07K14/725 ,  A61K39/395 ,  A61K35/17 ,  A61K39/00 ,  A61K38/00

Abstract: Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig) (e.g., an extracellular ligand-binding domain of F158 FCGR3A or V158 FCGR3A variant); a transmembrane domain (e.g., a transmembrane domain of CD8α); at least one co-stimulatory signaling domain (e.g., a co-stimulatory signaling domain of 4-1BB); and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) (e.g., a cytoplasmic signaling domain of CD3ζ). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors. Such immune cells can be used to enhance antibody-dependent cell-mediated cytotoxicity and/or to enhance antibody-based immunotherapy, such as cancer immunotherapy.

公开(公告)号：US10124041B2

公开(公告)日：2018-11-13

申请号：US15254984

申请日：2016-09-01

Applicant: UCL BUSINESS PLC ,  ST. JUDE CHILDREN'S RESEARCH HOSPITAL

Inventor： Amit Nathwani ,  Jenny McIntosh ,  Edward Tuddenham ,  Andrew Davidoff

IPC: C12N15/05 ,  A61K38/37 ,  C07K14/755 ,  A01K67/027 ,  A61K48/00

Abstract: There is provided a nucleic acid molecule comprising a nucleotide sequence encoding a factor VIII protein, wherein a B domain portion of the factor VIII protein is encoded by a nucleotides sequence between 90 and 111 nucleotides in length and has an amino acid sequence that is at least 85% identical to SEQ ID NO: 4 which comprises six asparagine residues. Also provided is a factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating Haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.

公开(公告)号：US20180311317A1

公开(公告)日：2018-11-01

申请号：US16031503

申请日：2018-07-10

Applicant: UCL BUSINESS PLC ,  St. Jude Children's Research Hospital

Inventor： Amit Nathwani ,  Jenny McIntosh ,  Edward Tuddenham ,  Andrew Davidoff

IPC: A61K38/37 ,  C07K14/755 ,  A01K67/027 ,  A61K48/00

Abstract: There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor VIII protein, wherein the portion of the nucleotide sequence encoding for the B domain of the factor VIII protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to SEQ ID NO: 4 and which comprises six asparagine residues. Also provided is a functional factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating haemophilia, e.g. haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.

公开(公告)号：US20180256558A1

公开(公告)日：2018-09-13

申请号：US15760560

申请日：2016-09-19

Applicant: Memorial Sloan Kettering Cancer Center ,  St. Jude Children's Research Hospital

Inventor： Jaeki MIN ,  Daniel C. SCOTT ,  Deepak BHASIN ,  Brenda A. SCHULMAN ,  Bhuvanesh SINGH ,  Jared T. HAMMILL ,  R. Kiplin GUY

IPC: A61K31/4545 ,  A61K31/17 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/451 ,  A61K31/506 ,  A61K31/437 ,  A61P15/16 ,  A61P31/12 ,  A61P31/04

CPC classification number: A61K31/4545 ,  A61K31/17 ,  A61K31/437 ,  A61K31/451 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/506 ,  A61P15/16 ,  A61P31/04 ,  A61P31/12 ,  C07D211/58 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/06 ,  C07D405/12 ,  C07D409/14 ,  C07D417/04 ,  C07D417/06 ,  C07D471/04

Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20180135014A1

公开(公告)日：2018-05-17

申请号：US15857166

申请日：2017-12-28

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. ,  NATIONAL UNIVERSITY OF SINGAPORE

Inventor： Dario Campana ,  Yu-Hsiang Chang

IPC: C12N5/0783 ,  C07K14/705 ,  C12N5/00 ,  A61K35/17 ,  C07K14/725

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K38/00 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/7056 ,  C07K2319/00 ,  C07K2319/70 ,  C12N5/0087 ,  C12N2510/00

Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.

公开(公告)号：US20180127469A1

公开(公告)日：2018-05-10

申请号：US15863673

申请日：2018-01-05

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL

Inventor： Richard E. Lee ,  Ying Zhao ,  Elizabeth Griffith ,  Zhong Zheng ,  Aman P. Singh

IPC: C07K11/02 ,  C07K7/06 ,  A61K38/15 ,  C12N9/50 ,  A61K45/06 ,  A61K38/00

Abstract: In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US09844587B2

公开(公告)日：2017-12-19

申请号：US14877322

申请日：2015-10-07

Applicant: St. Jude Children's Research Hospital

Inventor： Elaine Tuomanen ,  Elizabeth R. Mann

IPC: A61K39/02 ,  A61K39/09 ,  C07K14/315 ,  C07K14/47 ,  A61K39/00

CPC classification number: A61K39/092 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55583 ,  A61K2039/575 ,  A61K2039/6068 ,  A61K2039/645 ,  C07K14/3156 ,  C07K14/47 ,  C07K2319/00 ,  C07K2319/40

Abstract: Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof.